MyTomorrows

{{refimprove|date=January 2019}}

{{lowercase title}}

{{Infobox company

| name = myTomorrows

| logo = MYTOMORROWS_WITHOUTCLAIM.png

| type = Naamloze Vennootschap

| key_people = Ronald Brus (CEO),
Ronald Plasterk (CSO)

| industry = Healthcare, Pharmaceuticals

| products = Experimental drugs

| services =

| num_employees =

| website = {{URL|https://mytomorrows.com/|mytomorrows.com}}

| foundation = 2012

| location_city = Amsterdam

| location_country = Netherlands

}}

myTomorrows is the trade name of Impatients N.V., a globally active healthcare company.{{cite web|url=https://www.lemonde.fr/economie/article/2014/11/07/mytomorrows-derniere-chance-pour-des-patients_4520184_3234.html|publisher=Le Monde |title=MyTomorrows, dernière chance pour des patients|accessdate=21 November 2018}} The company is based in the Zuidas, Amsterdam, Netherlands. myTomorrows provides patients with unmet medical needs, and their doctors, information about treatment options worldwide and facilitates access to medicines in development.{{cite web|url=https://techcrunch.com/2017/01/09/mytomorrows-raises-10m/|publisher=TechCrunch |title=myTomorrows raises further 10M to help access drugs in development|accessdate=20 November 2018}}{{cite web|url=https://www.forbes.com/sites/bernardmunos/2016/12/08/patients-right-to-try-should-not-be-a-license-to-fleece-them/#4cef0c1a44ff|work=Forbes |title=Patients' Right To Try Should Not Be A License To Fleece Them|accessdate=8 January 2019}} Access to these medicines can be achieved via clinical trials, expanded access and off-label use.

myTomorrows was founded in 2012 by Ronald Brus, former CEO of the biotechnology company Crucell.{{cite web|url=https://medcitynews.com/2014/02/dutch-startup-offers-fast-lane-late-stage-drugs-patients-dwindling-options/|publisher=MedCity News |title=Dutch life science startup offers access to late-stage drugs for patients with few options|accessdate=20 November 2018|date=2014-02-20 }} In the beginning of its existence, myTomorrows has been characterized as innovative and controversial. In May 2013, MP Lea Bouwmeester asked parliamentary question about the company.{{cite web|url=https://www.nrc.nl/nieuws/2014/11/11/mytomorrows-is-de-uber-van-de-medicijnen-maar-dan-nog-iets-controversieler-a1499070|publisher=NRC Handelsblad |title=myTomorrows is de Uber van de medicijnen|accessdate=21 November 2018}} In December 2017, former minister Ronald Plasterk joined the company as Chief Scientific Officer.{{cite web|url=https://www.nu.nl/carriere/5004422/plasterk-gaat-farmabedrijf-mytomorrows.html|publisher=NU.nl |title=Plasterk gaat naar farmabedrijf Mytomorrows|accessdate=21 November 2018}}